BRAF and colorectal carcinoma: We also performed the first clinical trial, to our knowledge, of BRAF-targeted therapy combined with ICB specifically in patients with BRAFV600E CRC, evaluating the efficacy of combined BRAF, MEKi and PD-1 inhibition.